Skip to main content

2022 | Dermatologische Therapieverfahren | OriginalPaper | Buchkapitel

35. Hauterkrankungen

verfasst von : Prof. Dr. med. Hans Merk, Dr. rer. nat. Judith Günther

Erschienen in: Arzneiverordnungs-Report 2022

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Auf einen Blick

Verordnungsprofil Seit Jahren verändert sich das Verordnungsspektrum der zahlreicher dermatologischer Wirkstoffklassen nur marginal. Wie in den Vorjahren werden topische Glukokortikoide am häufigsten verordnet. Auf sie entfallen 43 von 100 Dermatikatagesdosen. Antimykotika und Psoriasismedikamente (jeweils 11 %), Medikamente bei aktinischer Keratose und Aknemedikamente (jeweils 7 %), Antiinfektiva und Warzenmedikamente (jeweils 5 %), Wundbehandlungsmedikamente und Antipruriginosa (jeweils 4 %) sowie Rosazeamedikamente (3 %) werden deutlich seltener verordnet. Aufgrund der dem Arzneiverordnungs-Report zugrunde liegenden Systematik werden in den Tabellen zu den Dermatikaverordnungen wesentliche Veränderungen in der Therapie chronisch-entzündlicher Dermatosen nicht vollständig abgebildet. Dies betrifft die Verwendung monoklonaler Antikörper (Biologika) und JAK-Inhibitoren bei der Behandlung schwerer Fälle von atopischer Dermatitis oder Psoriasis (Lauffer und Biedermann 2022; Griffiths et al. 2021).
Trend Die Verordnungen in den einzelnen Marktsegmenten werden weitgehend durch nationale und internationale Therapieempfehlungen gestützt. Die Gesamtverordnungsmenge bezogen auf DDD stieg 2021 im Vergleich zum Vorjahr um 3,9 %, mit deutlicheren Zuwächsen bei den Psoriasismedikamenten, den Aknemedikamenten und den Glukokortikoidtopika. Wesentliche Veränderungen in der Therapie der atopischen Dermatitis und der chronisch entzündlichen Hauterkrankungen werden vor allem bei Betrachtung der Kostenentwicklung deutlich: So entfällt 2021 weit über die Hälfte der gesamten dermatologischen Verordnungskosten von 2,7 Mrd. € auf die vier hier berücksichtigten monoklonalen Antikörper Dupilumab, Ustekinumab, Secukinumab, Guselkumab.
Literatur
Zurück zum Zitat Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, Schramm K, Heimstaedt-Muskett S, Masur C, Szeimies R (2021) A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol 185:315–322PubMedPubMedCentral Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, Schramm K, Heimstaedt-Muskett S, Masur C, Szeimies R (2021) A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol 185:315–322PubMedPubMedCentral
Zurück zum Zitat Alsterholm M, Flytström I, Bergbrant IM, Faergemann J (2010) Fusidic acid-resistant staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol 90:52–57PubMed Alsterholm M, Flytström I, Bergbrant IM, Faergemann J (2010) Fusidic acid-resistant staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol 90:52–57PubMed
Zurück zum Zitat Amann PM, Merk HF, Baron JM (2014) Retinoide in der Dermatopharmakologie. Hautarzt 65:98–105PubMed Amann PM, Merk HF, Baron JM (2014) Retinoide in der Dermatopharmakologie. Hautarzt 65:98–105PubMed
Zurück zum Zitat Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945–1960PubMed Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323:1945–1960PubMed
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (2006) Psychiatrische Reaktionen nach Terninafin (Lamisil®). Dtsch Arztebl 103:A3432 Arzneimittelkommission der deutschen Ärzteschaft (2006) Psychiatrische Reaktionen nach Terninafin (Lamisil®). Dtsch Arztebl 103:A3432
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (2013) Rhabdomyolyse nach Isotretinoin. Dtsch Arztebl 110:240 Arzneimittelkommission der deutschen Ärzteschaft (2013) Rhabdomyolyse nach Isotretinoin. Dtsch Arztebl 110:240
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (2019a) „Aus der UAW-Datenbank“: Rezidiv eines Morbus Crohn nach Behandlung einer atopischen Dermatitis mit Dupilumab. Dtsch Arztebl 116:A1919–A1920 Arzneimittelkommission der deutschen Ärzteschaft (2019a) „Aus der UAW-Datenbank“: Rezidiv eines Morbus Crohn nach Behandlung einer atopischen Dermatitis mit Dupilumab. Dtsch Arztebl 116:A1919–A1920
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (2019b) Retinoide (Acitretin, Adapalen, Alitretinoin, Bexaroten, lsotretinoin, Tazaroten und Tretinoin) – Aktualisierungen zu Teratogenität und neuropsychiatrischen Erkrankungen. Drug Saf 50 (www.akdae.de) Arzneimittelkommission der deutschen Ärzteschaft (2019b) Retinoide (Acitretin, Adapalen, Alitretinoin, Bexaroten, lsotretinoin, Tazaroten und Tretinoin) – Aktualisierungen zu Teratogenität und neuropsychiatrischen Erkrankungen. Drug Saf 50 (www.​akdae.​de)
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (2020) Brivudinhaltige Arzneimittel: Potenziell tödliche Toxizität von Fluoropyrimidinen bei der Anwendung kurz vor, gleichzeitig mit oder innerhalb von 4 Wochen nach Ende der Behandlung mit Brivudin. Drug Saf 31 (www.akdae.de) Arzneimittelkommission der deutschen Ärzteschaft (2020) Brivudinhaltige Arzneimittel: Potenziell tödliche Toxizität von Fluoropyrimidinen bei der Anwendung kurz vor, gleichzeitig mit oder innerhalb von 4 Wochen nach Ende der Behandlung mit Brivudin. Drug Saf 31 (www.​akdae.​de)
Zurück zum Zitat Aszodi N, Thurau S, Seegräber M, de Bruin-Weller M, Wollenberg A (2019) Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges 17:488–491PubMed Aszodi N, Thurau S, Seegräber M, de Bruin-Weller M, Wollenberg A (2019) Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges 17:488–491PubMed
Zurück zum Zitat Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V (2016) Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 175:873–881PubMedPubMedCentral Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V (2016) Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 175:873–881PubMedPubMedCentral
Zurück zum Zitat Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Turki H, Hall DB, Shear M, Baum P, Padula SJ, Thoma C (2019) Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med 380:981–983PubMed Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Turki H, Hall DB, Shear M, Baum P, Padula SJ, Thoma C (2019) Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med 380:981–983PubMed
Zurück zum Zitat Balak DMW, Fallah Arani S, Hajdarbegovic E, Hagemans CAF, Bramer WM, Thio HB, Neumann HAM (2016) Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies. Br J Dermatol 175:250–226PubMed Balak DMW, Fallah Arani S, Hajdarbegovic E, Hagemans CAF, Bramer WM, Thio HB, Neumann HAM (2016) Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies. Br J Dermatol 175:250–226PubMed
Zurück zum Zitat Balak DMW, Hajdarbegovic E, Bramer WM, Neumann HAM, Thio HB (2017) Progressive mulrifocal leukencephalopathy associated wirh fumaric acid etsres treatment in psoriasis patients. J Eur Acad Dermatol Venereol 31:1475–1482PubMed Balak DMW, Hajdarbegovic E, Bramer WM, Neumann HAM, Thio HB (2017) Progressive mulrifocal leukencephalopathy associated wirh fumaric acid etsres treatment in psoriasis patients. J Eur Acad Dermatol Venereol 31:1475–1482PubMed
Zurück zum Zitat Baron JM, Glatz M, Proksch E (2020) Optimal support of wound healing: new insights. Dermatology 236:593–600PubMed Baron JM, Glatz M, Proksch E (2020) Optimal support of wound healing: new insights. Dermatology 236:593–600PubMed
Zurück zum Zitat Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Mi-lutinovic M, Thaçi D (2017a) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 76:60–69.e9PubMed Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Mi-lutinovic M, Thaçi D (2017a) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 76:60–69.e9PubMed
Zurück zum Zitat Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB (2017b) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76:405–417PubMed Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB (2017b) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76:405–417PubMed
Zurück zum Zitat Booij MT, van De Kerkhof PC (2011) Acitretin revisited in the era of biologics. J Dermatolog Treat 22:86–89PubMed Booij MT, van De Kerkhof PC (2011) Acitretin revisited in the era of biologics. J Dermatolog Treat 22:86–89PubMed
Zurück zum Zitat Brodt HR (2013) Stille – Antibiotikatherapie. Klinik und Praxis der antiinfektiösen Behandlung, 12. Aufl. Schattauer, Stuttgart Brodt HR (2013) Stille – Antibiotikatherapie. Klinik und Praxis der antiinfektiösen Behandlung, 12. Aufl. Schattauer, Stuttgart
Zurück zum Zitat Brück J, Dringen R, Amasuno A, Pau-Charles I, Ghoreschi K (2018) A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol 27:611–624PubMed Brück J, Dringen R, Amasuno A, Pau-Charles I, Ghoreschi K (2018) A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol 27:611–624PubMed
Zurück zum Zitat Bundesministerium für Gesundheit (2015) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Secukinumab) vom: 27. Nov. 2015. BAnz AT 29. Dez. 2015 B4) Bundesministerium für Gesundheit (2015) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Secukinumab) vom: 27. Nov. 2015. BAnz AT 29. Dez. 2015 B4)
Zurück zum Zitat Bundesministerium für Gesundheit (2017) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Secukinumab (Neubewertung aufgrund neuer wissenschaftlicher Erkenntnisse)) vom: 17. Aug. 2017. BAnz AT 12. Sept. 2017 B2) Bundesministerium für Gesundheit (2017) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Secukinumab (Neubewertung aufgrund neuer wissenschaftlicher Erkenntnisse)) vom: 17. Aug. 2017. BAnz AT 12. Sept. 2017 B2)
Zurück zum Zitat Bundesministerium für Gesundheit (2018) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Guselkumab) vom: 17. Mai 2018. BAnz AT 4. Juli 2018 B2) Bundesministerium für Gesundheit (2018) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) ((Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Guselkumab) vom: 17. Mai 2018. BAnz AT 4. Juli 2018 B2)
Zurück zum Zitat Bundesministerium für Gesundheit (2021) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Guselkumab (neues Anwendungsgebiet: Psoriasis-Arthritis) vom: 20. Mai 2021. BAnz AT 29. Juni 2021 B5) Bundesministerium für Gesundheit (2021) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Guselkumab (neues Anwendungsgebiet: Psoriasis-Arthritis) vom: 20. Mai 2021. BAnz AT 29. Juni 2021 B5)
Zurück zum Zitat Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR (2016) New developments in the treatment of rosacea – role of once-daily ivermectin cream. Clin Cosmet Investig Dermatol 9:71–77PubMedPubMedCentral Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR (2016) New developments in the treatment of rosacea – role of once-daily ivermectin cream. Clin Cosmet Investig Dermatol 9:71–77PubMedPubMedCentral
Zurück zum Zitat Chroni E, Monastirli A, Tsambaos D (2010) Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf 33:25–34PubMed Chroni E, Monastirli A, Tsambaos D (2010) Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf 33:25–34PubMed
Zurück zum Zitat Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, Gieler U, Kinberger M, Klövekorn W, Kuna AC, Läuchli S, Lehmann P, Nast A, Pleyer U, Schaller M, Schöfer H, Steinhoff M, Schwennesen T, Werner RN, Zierhut M, Reinholz M (2022) S2k-Leitlinie: Rosazea. J Dtsch Dermatol Ges 20:1147–1167PubMed Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, Gieler U, Kinberger M, Klövekorn W, Kuna AC, Läuchli S, Lehmann P, Nast A, Pleyer U, Schaller M, Schöfer H, Steinhoff M, Schwennesen T, Werner RN, Zierhut M, Reinholz M (2022) S2k-Leitlinie: Rosazea. J Dtsch Dermatol Ges 20:1147–1167PubMed
Zurück zum Zitat Clerens I, Goossens A (2017) Allergic contact dermatitis caused by panthenol: a rare but relevant sensitizer. Contact Derm 76:122–123 Clerens I, Goossens A (2017) Allergic contact dermatitis caused by panthenol: a rare but relevant sensitizer. Contact Derm 76:122–123
Zurück zum Zitat Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB Jr, Feldman SR (2007) Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 6:495–498PubMed Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB Jr, Feldman SR (2007) Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 6:495–498PubMed
Zurück zum Zitat Connor TH, Stoeckel M, Evrard J, Legator MS (1977) The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res 37:629–633PubMed Connor TH, Stoeckel M, Evrard J, Legator MS (1977) The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res 37:629–633PubMed
Zurück zum Zitat Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES (2020) Field cancerization: treatment. J Am Acad Dermatol 83:719–730PubMed Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, Schmults CD, Arron ST, Ruiz ES (2020) Field cancerization: treatment. J Am Acad Dermatol 83:719–730PubMed
Zurück zum Zitat Czaika VA, Zuberbier T (2015) Lokale Kombinationstherapie bei entzündlichen Dermatomykosen. Review zu den Therapieempfehlungen in nationalen und internationalen Leitlinien. Hautarzt 66:360–369PubMed Czaika VA, Zuberbier T (2015) Lokale Kombinationstherapie bei entzündlichen Dermatomykosen. Review zu den Therapieempfehlungen in nationalen und internationalen Leitlinien. Hautarzt 66:360–369PubMed
Zurück zum Zitat Dall’Oglio F, D’Amico V, Nasca MR, Micali G (2012) Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol 13:73–96PubMed Dall’Oglio F, D’Amico V, Nasca MR, Micali G (2012) Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol 13:73–96PubMed
Zurück zum Zitat Darkes MJM, Scott LJ, Goa KL (2003) Terbinafine. A review of its use in onychomycosis in adults. Am J Clin Dermatol 4:39–65PubMed Darkes MJM, Scott LJ, Goa KL (2003) Terbinafine. A review of its use in onychomycosis in adults. Am J Clin Dermatol 4:39–65PubMed
Zurück zum Zitat Dissemond J, Gerber V, Kramer A, Riepe G, Strohal R, Vasel-Biergans A, Eberlein T (2009) Praxisorientierte Expertenempfehlung zur Behandlung kritisch kolonisierter und lokal infizierter Wunden mit Polihexanid. WundManagement 2009:62–68 Dissemond J, Gerber V, Kramer A, Riepe G, Strohal R, Vasel-Biergans A, Eberlein T (2009) Praxisorientierte Expertenempfehlung zur Behandlung kritisch kolonisierter und lokal infizierter Wunden mit Polihexanid. WundManagement 2009:62–68
Zurück zum Zitat Dittmann K, Schmidt T, Müller G, Cuny C, Holtfreter S, Troitzsch D, Pfaff P, Hübner NO (2019) Susceptibility of livestock-associated methicillin-resistant staphylococcus aureus (LA-MRSA) to chlorhexidine digluconate, octenidine dihydrochloride, polyhexanide, PVP-iodine and triclosan in comparison to hospital-acquired MRSA (HA-MRSA) and community-aquired MRSA (CA-MRSA): a standardized comparison. Antimicrob Resist Infect Control 8:122PubMedPubMedCentral Dittmann K, Schmidt T, Müller G, Cuny C, Holtfreter S, Troitzsch D, Pfaff P, Hübner NO (2019) Susceptibility of livestock-associated methicillin-resistant staphylococcus aureus (LA-MRSA) to chlorhexidine digluconate, octenidine dihydrochloride, polyhexanide, PVP-iodine and triclosan in comparison to hospital-acquired MRSA (HA-MRSA) and community-aquired MRSA (CA-MRSA): a standardized comparison. Antimicrob Resist Infect Control 8:122PubMedPubMedCentral
Zurück zum Zitat Dréno B, Bettoli V, Ochsendorf F, Layton AM, Perez M, Dakovic R, Gollnick H (2014) Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. Eur J Dermatol 24:201–209PubMed Dréno B, Bettoli V, Ochsendorf F, Layton AM, Perez M, Dakovic R, Gollnick H (2014) Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. Eur J Dermatol 24:201–209PubMed
Zurück zum Zitat Drucker CR (2012) Update on topical antibiotics in dermatology. Dermatol Ther 25:6–11PubMed Drucker CR (2012) Update on topical antibiotics in dermatology. Dermatol Ther 25:6–11PubMed
Zurück zum Zitat Ebbelaar CCF, Venema AW, Van Dijk MR (2018) Topical Ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations. Dermatol Ther (Heidelb) 8:379–387PubMed Ebbelaar CCF, Venema AW, Van Dijk MR (2018) Topical Ivermectin in the treatment of papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations. Dermatol Ther (Heidelb) 8:379–387PubMed
Zurück zum Zitat Eberlein T, Assadian O (2010) Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination. Skin Pharmacol Physiol 23(Suppl 1):45–51PubMed Eberlein T, Assadian O (2010) Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination. Skin Pharmacol Physiol 23(Suppl 1):45–51PubMed
Zurück zum Zitat Ebner F, Heller A, Rippke F, Tausch I (2002) Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 3:427–433PubMed Ebner F, Heller A, Rippke F, Tausch I (2002) Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 3:427–433PubMed
Zurück zum Zitat Erbagci Z (2004) Topical therapy for dermatophytoses. Should corticosteroids be included? Am J Clin Dermatol 5:375–384PubMed Erbagci Z (2004) Topical therapy for dermatophytoses. Should corticosteroids be included? Am J Clin Dermatol 5:375–384PubMed
Zurück zum Zitat European Medicines Agency (2009) Committee on herbal medicinal products (HMPC) assessment report on Hamamelis virginiana L, Cortex; Hamamelis virginiana L, Folium, Hamamelis virginiana L. Folium et cortex aut ramunculus destillatum. http://www.ema.europa.eu/ema/. Zugegriffen 28. September 2022 European Medicines Agency (2009) Committee on herbal medicinal products (HMPC) assessment report on Hamamelis virginiana L, Cortex; Hamamelis virginiana L, Folium, Hamamelis virginiana L. Folium et cortex aut ramunculus destillatum. http://​www.​ema.​europa.​eu/​ema/​. Zugegriffen 28. September 2022
Zurück zum Zitat European Medicines Agency (EMA) (2015) Committee on herbal medicinal Produkts (HMPC) assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum. http://www.ema.europa.eu/ema/. Zugegriffen 28. September 2022 European Medicines Agency (EMA) (2015) Committee on herbal medicinal Produkts (HMPC) assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum. http://​www.​ema.​europa.​eu/​ema/​. Zugegriffen 28. September 2022
Zurück zum Zitat Ference JD, Last AR (2009) Choosing topical corticosteroids. Am Fam Physician 79:135–140PubMed Ference JD, Last AR (2009) Choosing topical corticosteroids. Am Fam Physician 79:135–140PubMed
Zurück zum Zitat Fjeld H, Lingaas E (2016) Polyhexanide – safety and efficacy as an antiseptic. Tidsskr Nor Laegeforen 136:707–711PubMed Fjeld H, Lingaas E (2016) Polyhexanide – safety and efficacy as an antiseptic. Tidsskr Nor Laegeforen 136:707–711PubMed
Zurück zum Zitat Fluhr JW, Degitz K (2010) Antibiotika, Azelainsäure und Benzoylperoxid in der topische Aknetherapie. J Dtsch Dermatol Ges 8(Suppl 1):S24–S30PubMed Fluhr JW, Degitz K (2010) Antibiotika, Azelainsäure und Benzoylperoxid in der topische Aknetherapie. J Dtsch Dermatol Ges 8(Suppl 1):S24–S30PubMed
Zurück zum Zitat Fölster-Holst R, Latussek E (2007) Synthetic tannins in dermatology – a therapeutic option in a variety of pediatric dermatoses. Pediatr Dermatol 24:296–301PubMed Fölster-Holst R, Latussek E (2007) Synthetic tannins in dermatology – a therapeutic option in a variety of pediatric dermatoses. Pediatr Dermatol 24:296–301PubMed
Zurück zum Zitat Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M (2012) Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 166:633–641PubMedPubMedCentral Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, Liu Y, Leoni M (2012) Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 166:633–641PubMedPubMedCentral
Zurück zum Zitat Francis NA, Ridd MJ, Thomas-Jones E, Butler CC, Hood K, Shepherd V, Marwick CA, Huang C, Longo M, Wootton M, Sullivan F, CREAM Trial Management Group (2017) Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. Ann Fam Med 15:124–130PubMedPubMedCentral Francis NA, Ridd MJ, Thomas-Jones E, Butler CC, Hood K, Shepherd V, Marwick CA, Huang C, Longo M, Wootton M, Sullivan F, CREAM Trial Management Group (2017) Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. Ann Fam Med 15:124–130PubMedPubMedCentral
Zurück zum Zitat Freimooser S, Traidl S, Werfel T (2022) Entwicklung von neuen topischen Substanzen zur Therapie der atopischen Dermatitis. Hautarzt 73:514–519 Freimooser S, Traidl S, Werfel T (2022) Entwicklung von neuen topischen Substanzen zur Therapie der atopischen Dermatitis. Hautarzt 73:514–519
Zurück zum Zitat Gaspari A, Tyring SK, Rosen T (2009) Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 8:467–474 Gaspari A, Tyring SK, Rosen T (2009) Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 8:467–474
Zurück zum Zitat Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL (2017) Progressive multifocal leukencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 264:1155–1164PubMed Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL (2017) Progressive multifocal leukencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 264:1155–1164PubMed
Zurück zum Zitat Glenn CJ, Kobraei KB, Russo JJ (2011) New-onset psoriasis associated with adalimumab: a report of two cases. Dermatol Online J 17:15PubMed Glenn CJ, Kobraei KB, Russo JJ (2011) New-onset psoriasis associated with adalimumab: a report of two cases. Dermatol Online J 17:15PubMed
Zurück zum Zitat Gloor M (1982) Pharmakologie dermatologischer Externa. Springer, Berlin, Heidelberg, New York Gloor M (1982) Pharmakologie dermatologischer Externa. Springer, Berlin, Heidelberg, New York
Zurück zum Zitat Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N (2017) Treatment of rosacea with concomitant use of topical Ivermectin 1% cream and Brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol 16:909–916PubMed Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N (2017) Treatment of rosacea with concomitant use of topical Ivermectin 1% cream and Brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol 16:909–916PubMed
Zurück zum Zitat Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M (2009) Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 161:1180–1189PubMed Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M (2009) Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 161:1180–1189PubMed
Zurück zum Zitat Goreshi R, Samrao A, Ehst BD (2012) A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. J Drugs Dermatol 11:1422–1426PubMed Goreshi R, Samrao A, Ehst BD (2012) A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. J Drugs Dermatol 11:1422–1426PubMed
Zurück zum Zitat Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128PubMed Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128PubMed
Zurück zum Zitat Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. Lancet 397:1301–1315PubMed Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. Lancet 397:1301–1315PubMed
Zurück zum Zitat Grover C, Khurana A (2012) An update on treatment of onychomycosis. Mycoses 55:541–551PubMed Grover C, Khurana A (2012) An update on treatment of onychomycosis. Mycoses 55:541–551PubMed
Zurück zum Zitat Gupta AK, Cherman AM, Tyring SK (2005) Viral and nonviral uses of imiquimod: a review. J Cut Med Surg 8:338–352 Gupta AK, Cherman AM, Tyring SK (2005) Viral and nonviral uses of imiquimod: a review. J Cut Med Surg 8:338–352
Zurück zum Zitat Hahn C, Röseler S, Fritzsche R, Schneider R, Merk HF (1993) Allergic contact reaction to dexpanthenol: lymphocyte transformation test and evidence for microsomal-dependent metabolism of the allergen. Contact Dermat 28:81–83 Hahn C, Röseler S, Fritzsche R, Schneider R, Merk HF (1993) Allergic contact reaction to dexpanthenol: lymphocyte transformation test and evidence for microsomal-dependent metabolism of the allergen. Contact Dermat 28:81–83
Zurück zum Zitat Hayden MK, Lolans K, Haffenreffer K, Avery TR, Kleinman K, Li H, Kaganov RE, Lankiewicz J, Moody J, Septimus E, Weinstein RA, Hickok J, Jernigan J, Perlin JB, Platt R, Huang SS (2016) Chlorhexidine and mupirocin susceptibility of methicillin-resistant staphylococcus aureus isolates in the REDUCE-MRSA trial. J Clin Microbiol 54:2735–2742PubMedPubMedCentral Hayden MK, Lolans K, Haffenreffer K, Avery TR, Kleinman K, Li H, Kaganov RE, Lankiewicz J, Moody J, Septimus E, Weinstein RA, Hickok J, Jernigan J, Perlin JB, Platt R, Huang SS (2016) Chlorhexidine and mupirocin susceptibility of methicillin-resistant staphylococcus aureus isolates in the REDUCE-MRSA trial. J Clin Microbiol 54:2735–2742PubMedPubMedCentral
Zurück zum Zitat Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013a) Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol 27:399–410PubMed Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013a) Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol 27:399–410PubMed
Zurück zum Zitat Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013b) Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 27:931–951PubMed Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013b) Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 27:931–951PubMed
Zurück zum Zitat Hengge UR, Ruzicka T, Schartz RA, Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54:1–15PubMed Hengge UR, Ruzicka T, Schartz RA, Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54:1–15PubMed
Zurück zum Zitat Hund M, Sinkgraven R, Rzany B (2004) Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin®) bei fokaler Hyperhidrose. J Dtsch Dermatol Ges 2:343–349PubMed Hund M, Sinkgraven R, Rzany B (2004) Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin®) bei fokaler Hyperhidrose. J Dtsch Dermatol Ges 2:343–349PubMed
Zurück zum Zitat Jacobi A, Mayer A, Augustin M (2015) Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther 5:1–18 Jacobi A, Mayer A, Augustin M (2015) Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review. Dermatol Ther 5:1–18
Zurück zum Zitat Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, Quaedvlieg PJF, Essers BAB, Steijlen PM, Kelleners-Smeets NWJ, Mosterd K (2019) Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 380:935–946PubMed Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, Quaedvlieg PJF, Essers BAB, Steijlen PM, Kelleners-Smeets NWJ, Mosterd K (2019) Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 380:935–946PubMed
Zurück zum Zitat Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011PubMed Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011PubMed
Zurück zum Zitat Ju HJ, Han JH, Kim MS, Lee SH, Shin JW, Choi M, Jeong KH, Han TY, Choi CW, Lee HJ, Oh SH, Lee SH, Kim DH, Shin J, Lee JH, Kim SS, Kang HY, Chang SE, Kim JS, Lee DY, Choi GS, Suh DH, Kim CY, Park CJ, Kim KH, Lee AY, Park CK, Lee MH, Bae JM (2021) The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo. J Am Acad Dermatol 84:1619–1627PubMed Ju HJ, Han JH, Kim MS, Lee SH, Shin JW, Choi M, Jeong KH, Han TY, Choi CW, Lee HJ, Oh SH, Lee SH, Kim DH, Shin J, Lee JH, Kim SS, Kang HY, Chang SE, Kim JS, Lee DY, Choi GS, Suh DH, Kim CY, Park CJ, Kim KH, Lee AY, Park CK, Lee MH, Bae JM (2021) The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo. J Am Acad Dermatol 84:1619–1627PubMed
Zurück zum Zitat van de Kerkhof PC, Kragballe K, Segaert S, Lebwohl M, International Psoriasis Council (2011) Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol 25:1130–1139PubMed van de Kerkhof PC, Kragballe K, Segaert S, Lebwohl M, International Psoriasis Council (2011) Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol 25:1130–1139PubMed
Zurück zum Zitat Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH (2020) The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs 80:99–113PubMedPubMedCentral Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH (2020) The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs 80:99–113PubMedPubMedCentral
Zurück zum Zitat Koburger T, Hübner NO, Braun M, Siebert J, Kramer A (2010) Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 65:1712–1719PubMed Koburger T, Hübner NO, Braun M, Siebert J, Kramer A (2010) Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 65:1712–1719PubMed
Zurück zum Zitat Koo JYM (2005) New developments in topical sequential therapy for psoriasis. Skin Therapy Lett 10:1–4PubMed Koo JYM (2005) New developments in topical sequential therapy for psoriasis. Skin Therapy Lett 10:1–4PubMed
Zurück zum Zitat von Krogh G (1978) Topical treatment of penile condylomata acuminata with podophyllin, podophyllotoxin and colchicine. A comparative study. Acta Derm Venereol 58:163–168 von Krogh G (1978) Topical treatment of penile condylomata acuminata with podophyllin, podophyllotoxin and colchicine. A comparative study. Acta Derm Venereol 58:163–168
Zurück zum Zitat Kujath P, Michelsen A (2008) Wunden – von der Physiologie zum Verband. Dtsch Arztebl 105:239–248 Kujath P, Michelsen A (2008) Wunden – von der Physiologie zum Verband. Dtsch Arztebl 105:239–248
Zurück zum Zitat Küster W, Bohnsack K, Rippke F, Upmeyer HJ, Groll S, Traupe H (1998) Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 196:217–222PubMed Küster W, Bohnsack K, Rippke F, Upmeyer HJ, Groll S, Traupe H (1998) Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 196:217–222PubMed
Zurück zum Zitat Kyoreva M, Li Y, Hoosenally M, Hardman-Smart J, Morrison K, Tosi I, Tolaini M, Barinaga G, Stockinger B, Mrowietz U, Nestle FO, Smith CH, Barker JN, Di Meglio P (2021) CYP1A1 Enzymatic activity influences skin inflammation via regulation of the AHR pathway. J Invest Dermatol 141:1553–1563PubMedPubMedCentral Kyoreva M, Li Y, Hoosenally M, Hardman-Smart J, Morrison K, Tosi I, Tolaini M, Barinaga G, Stockinger B, Mrowietz U, Nestle FO, Smith CH, Barker JN, Di Meglio P (2021) CYP1A1 Enzymatic activity influences skin inflammation via regulation of the AHR pathway. J Invest Dermatol 141:1553–1563PubMedPubMedCentral
Zurück zum Zitat Lachapelle JM (2014) A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol 24:3–9PubMed Lachapelle JM (2014) A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol 24:3–9PubMed
Zurück zum Zitat Lam M, Zhu JW, Tadrous M, Drucker AM (2021) Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol 157:549–558PubMed Lam M, Zhu JW, Tadrous M, Drucker AM (2021) Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol 157:549–558PubMed
Zurück zum Zitat Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigur-geirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C (2014) Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 371:326–338PubMed Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigur-geirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C (2014) Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 371:326–338PubMed
Zurück zum Zitat Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K (2015) Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 172:1371–1383PubMed Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K (2015) Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 172:1371–1383PubMed
Zurück zum Zitat Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L (2018) Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 178:114–123PubMed Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L (2018) Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 178:114–123PubMed
Zurück zum Zitat Langner A, Sheehan-Dare R, Layton A (2007) A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 21:311–319PubMed Langner A, Sheehan-Dare R, Layton A (2007) A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 21:311–319PubMed
Zurück zum Zitat Lansdown AB, Mirastschijski U, Stubbs N, Scanlon E, Ågren MS (2007) Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen 15:2–16PubMed Lansdown AB, Mirastschijski U, Stubbs N, Scanlon E, Ågren MS (2007) Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen 15:2–16PubMed
Zurück zum Zitat Lauffer F, Biedermann T (2022) Einschätzungen zur Therapie der moderaten bis schweren atopischen Dermatitis mit Januskinaseinhibitoren. Hautarzt 73:520–528 Lauffer F, Biedermann T (2022) Einschätzungen zur Therapie der moderaten bis schweren atopischen Dermatitis mit Januskinaseinhibitoren. Hautarzt 73:520–528
Zurück zum Zitat Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM (2015) Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol 29:2405–2410PubMedPubMedCentral Layton AM, Schaller M, Homey B, Hofmann MA, Bewley AP, Lehmann P, Nohlgård C, Sarwer DB, Kerrouche N, Ma YM (2015) Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol 29:2405–2410PubMedPubMedCentral
Zurück zum Zitat Lohde H, Stahlmann R (Hrsg.) (2004): Nadifloxacin – irrationaler Einsatz eines Fluorchinolons zur lokalen Aknetherapie. Zeitschr Chemother 25: 27–29 Lohde H, Stahlmann R (Hrsg.) (2004): Nadifloxacin – irrationaler Einsatz eines Fluorchinolons zur lokalen Aknetherapie. Zeitschr Chemother 25: 27–29
Zurück zum Zitat Løkkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G (1996) Skin treatment with Bepanthen cream versus no cream during radiotherapy. Acta Oncol 35:1021–1026PubMed Løkkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G (1996) Skin treatment with Bepanthen cream versus no cream during radiotherapy. Acta Oncol 35:1021–1026PubMed
Zurück zum Zitat Luger TA, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Niedner R, Röcken M, Ruzicka T, Schwarz T (2004) Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. J Deut Dermatol Gesell 2:629–634 Luger TA, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Niedner R, Röcken M, Ruzicka T, Schwarz T (2004) Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. J Deut Dermatol Gesell 2:629–634
Zurück zum Zitat McClellan KJ, Noble S (2000) Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol 1:191–199PubMed McClellan KJ, Noble S (2000) Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol 1:191–199PubMed
Zurück zum Zitat McNeil JC, Hulten KG, Kaplan SL, Mason EO (2014) Decreased susceptibilities to retapamulin, mupirocin, and chlorhexidine among staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children. Antimicrob Agents Chemother 58:2878–2883PubMedPubMedCentral McNeil JC, Hulten KG, Kaplan SL, Mason EO (2014) Decreased susceptibilities to retapamulin, mupirocin, and chlorhexidine among staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children. Antimicrob Agents Chemother 58:2878–2883PubMedPubMedCentral
Zurück zum Zitat Menezes de Padua CA, Schnuch A, Nink K, Pfahlberg A, Uter W (2008) Allergic contact dermatitis to topical drugs – epidemiological risk assessment. Pharmacoepidemiol Drug Saf 17:813–821 Menezes de Padua CA, Schnuch A, Nink K, Pfahlberg A, Uter W (2008) Allergic contact dermatitis to topical drugs – epidemiological risk assessment. Pharmacoepidemiol Drug Saf 17:813–821
Zurück zum Zitat Merk HF (2021) Hauttumoren im Visier. Teil 1: Klassische medikamentöse Behandlung. Teil 2: Fortschritte in der medikamentösen Therapie von Hauttumoren. Dtsch Apoth Ztg 161:36–46 Merk HF (2021) Hauttumoren im Visier. Teil 1: Klassische medikamentöse Behandlung. Teil 2: Fortschritte in der medikamentösen Therapie von Hauttumoren. Dtsch Apoth Ztg 161:36–46
Zurück zum Zitat Merk HF (2007) Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 46:12–18PubMed Merk HF (2007) Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 46:12–18PubMed
Zurück zum Zitat Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, Tebbs VM, Pau-Charles I (2017) Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(®) – and placebo-controlled trial (BRIDGE). Br J Dermatol 176:615–623PubMed Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, Tebbs VM, Pau-Charles I (2017) Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(®) – and placebo-controlled trial (BRIDGE). Br J Dermatol 176:615–623PubMed
Zurück zum Zitat Muller A, Talon D, Potier A, Belle E, Cappelier G, Bertrand X (2005) Use of intranasal mupirocin to prevent methicillin-resistant staphylococcus aureus infection in intensive care units. Crit Care 9:R246–R250PubMedPubMedCentral Muller A, Talon D, Potier A, Belle E, Cappelier G, Bertrand X (2005) Use of intranasal mupirocin to prevent methicillin-resistant staphylococcus aureus infection in intensive care units. Crit Care 9:R246–R250PubMedPubMedCentral
Zurück zum Zitat Müller C, Berensmeier A, Hamm H, Dirschka T, Reich K, Fischer T, Rzany B (2013) Efficacy and safety of methantheline bromide (Vagantin(®)) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol 27:1278–1284PubMed Müller C, Berensmeier A, Hamm H, Dirschka T, Reich K, Fischer T, Rzany B (2013) Efficacy and safety of methantheline bromide (Vagantin(®)) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol 27:1278–1284PubMed
Zurück zum Zitat Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C (2021) S3-Leitlinie Therapie der Psoriasis vulgaris AWMF-Register-Nr.: 013–001 mit Appendix. Stand: 19.02.2021 , gültig bis 30.09.2022. https://www.awmf.org/leitlinien/detail/ll/013-001.html Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C (2021) S3-Leitlinie Therapie der Psoriasis vulgaris AWMF-Register-Nr.: 013–001 mit Appendix. Stand: 19.02.2021 , gültig bis 30.09.2022. https://​www.​awmf.​org/​leitlinien/​detail/​ll/​013-001.​html
Zurück zum Zitat Nguyen ED, Gabel CK, Kroshinsky D (2021) Assessing the incidence of skin and soft tissue infection in patients on biologics. J Am Acad Dermatol 85:604–610PubMed Nguyen ED, Gabel CK, Kroshinsky D (2021) Assessing the incidence of skin and soft tissue infection in patients on biologics. J Am Acad Dermatol 85:604–610PubMed
Zurück zum Zitat Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP (2015) PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 372:1474–1476PubMed Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP (2015) PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 372:1474–1476PubMed
Zurück zum Zitat Nímia HH, Carvalho VF, Isaac C, Souza FÁ, Gemperli R, Paggiaro AO (2019) Comparative study of Silver Sulfadiazine with other materials for healing and infection prevention in burns: a systematic review and meta-analysis. Burns 45:282–292PubMed Nímia HH, Carvalho VF, Isaac C, Souza FÁ, Gemperli R, Paggiaro AO (2019) Comparative study of Silver Sulfadiazine with other materials for healing and infection prevention in burns: a systematic review and meta-analysis. Burns 45:282–292PubMed
Zurück zum Zitat Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH (2020) No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol 83:375–381PubMed Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH (2020) No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol 83:375–381PubMed
Zurück zum Zitat Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol 73:37–49PubMed Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol 73:37–49PubMed
Zurück zum Zitat Patry J, Blanchette V (2017) Enzymatic debridement with collagenase in wounds and ulcers: a systematic review and meta-analysis. Int Wound J 14:1055–1065PubMedPubMedCentral Patry J, Blanchette V (2017) Enzymatic debridement with collagenase in wounds and ulcers: a systematic review and meta-analysis. Int Wound J 14:1055–1065PubMedPubMedCentral
Zurück zum Zitat Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ES-TEEM 2). Br J Dermatol 173:1387–1399PubMed Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ES-TEEM 2). Br J Dermatol 173:1387–1399PubMed
Zurück zum Zitat Post B, Jänner M (1971) Zur Indikation der Gerbstofftherapie in der Dermatologie. Klinische Erfahrungen mit Tannosynt. Ther Ggw 110:1477–1494PubMed Post B, Jänner M (1971) Zur Indikation der Gerbstofftherapie in der Dermatologie. Klinische Erfahrungen mit Tannosynt. Ther Ggw 110:1477–1494PubMed
Zurück zum Zitat Raharja A, Mahil SK, Barker JN (2021) Psoriasis: a brief overview. Clin Med (Lond) 21:170–173PubMed Raharja A, Mahil SK, Barker JN (2021) Psoriasis: a brief overview. Clin Med (Lond) 21:170–173PubMed
Zurück zum Zitat Ramos-e-Silva M, Lima CM, Schechtman R, Trope MB, Carneiro S (2012) Systemic mycoses in immunodepressed patients (AIDS). Clin Dermatol 30:616–627PubMed Ramos-e-Silva M, Lima CM, Schechtman R, Trope MB, Carneiro S (2012) Systemic mycoses in immunodepressed patients (AIDS). Clin Dermatol 30:616–627PubMed
Zurück zum Zitat Rashaan ZM, Krijnen P, Klamer RR, Schipper IB, Dekkers OM, Breederveld RS (2014) Nonsilver treatment vs. silver sulfadiazine in treatment of partial-thickness burn wounds in children: a systematic review and meta-analysis. Wound Repair Regen 22:473–482PubMed Rashaan ZM, Krijnen P, Klamer RR, Schipper IB, Dekkers OM, Breederveld RS (2014) Nonsilver treatment vs. silver sulfadiazine in treatment of partial-thickness burn wounds in children: a systematic review and meta-analysis. Wound Repair Regen 22:473–482PubMed
Zurück zum Zitat Rathi SK, D’Souza P (2012) Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol 57:251–259PubMedPubMedCentral Rathi SK, D’Souza P (2012) Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol 57:251–259PubMedPubMedCentral
Zurück zum Zitat Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J (2017a) The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 31:507–517PubMed Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J (2017a) The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 31:507–517PubMed
Zurück zum Zitat Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB (2017b) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76:418–431PubMed Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB (2017b) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76:418–431PubMed
Zurück zum Zitat Ring J, Fröhlich HH (1985) Wirkstoffe in der dermatologischen Therapie, 2. Aufl. Springer, Berlin Heidelberg, New York Ring J, Fröhlich HH (1985) Wirkstoffe in der dermatologischen Therapie, 2. Aufl. Springer, Berlin Heidelberg, New York
Zurück zum Zitat Rotta I, Sanchez A, Gonçalves PR, Otuki MF, Correr CJ (2012) Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol 166:927–933PubMed Rotta I, Sanchez A, Gonçalves PR, Otuki MF, Correr CJ (2012) Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol 166:927–933PubMed
Zurück zum Zitat Ruzicka T (2006) Methylprednisolone aceponate in eczema and other inflammatory skin disorders – a clinical update. Int J Clin Pract 60:85–92PubMed Ruzicka T (2006) Methylprednisolone aceponate in eczema and other inflammatory skin disorders – a clinical update. Int J Clin Pract 60:85–92PubMed
Zurück zum Zitat Saco M, Howe N, Nathoo R, Cherpelis B (2016) Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success. Dermatol Online J 22:13030/qt7ph5v17zPubMed Saco M, Howe N, Nathoo R, Cherpelis B (2016) Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success. Dermatol Online J 22:13030/qt7ph5v17zPubMed
Zurück zum Zitat Samrao A, Cockerell CJ (2013) Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol 14:273–237PubMed Samrao A, Cockerell CJ (2013) Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol 14:273–237PubMed
Zurück zum Zitat Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB (2019) Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol 33:355–366PubMed Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB (2019) Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol 33:355–366PubMed
Zurück zum Zitat Schaller M, Friedrich M, Papini M, Pujol RM, Veraldi S (2016) Topical antifungal-corticosteroid combination therapy for the treatment of superficial mycoses: conclusions of an expert panel meeting. Mycoses 59:365–373PubMed Schaller M, Friedrich M, Papini M, Pujol RM, Veraldi S (2016) Topical antifungal-corticosteroid combination therapy for the treatment of superficial mycoses: conclusions of an expert panel meeting. Mycoses 59:365–373PubMed
Zurück zum Zitat Schöfer H, Simonsen L (2010) Fusidic acid in dermatology: an updated review. Eur J Dermatol 20:6–15PubMed Schöfer H, Simonsen L (2010) Fusidic acid in dermatology: an updated review. Eur J Dermatol 20:6–15PubMed
Zurück zum Zitat Senner S, Eicher L, Aszodi N, Prinz JC, French LE, Wollenberg A (2020) Psoriasis bei Dupilumab-behandeltem atopischem Ekzem. Hautarzt 71:383–386PubMed Senner S, Eicher L, Aszodi N, Prinz JC, French LE, Wollenberg A (2020) Psoriasis bei Dupilumab-behandeltem atopischem Ekzem. Hautarzt 71:383–386PubMed
Zurück zum Zitat Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR (2011) Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 67:e179–e185PubMed Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR (2011) Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 67:e179–e185PubMed
Zurück zum Zitat Singal A, Khanna D (2011) Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol 77:659–672PubMed Singal A, Khanna D (2011) Onychomycosis: diagnosis and management. Indian J Dermatol Venereol Leprol 77:659–672PubMed
Zurück zum Zitat Singh S, Fatima Z, Hameed S (2015) Predisposing factors endorsing Candida infections. Infez Med 23:211–223PubMed Singh S, Fatima Z, Hameed S (2015) Predisposing factors endorsing Candida infections. Infez Med 23:211–223PubMed
Zurück zum Zitat Solares CA, Batra PS, Hall GS, Citardi MJ (2006) Treatment of chronic rhinosinusitis exacerbations due to methicillin-resistant staphylococcus aureus with mupirocin irrigations. Am J Otolaryngol 27:161–165PubMed Solares CA, Batra PS, Hall GS, Citardi MJ (2006) Treatment of chronic rhinosinusitis exacerbations due to methicillin-resistant staphylococcus aureus with mupirocin irrigations. Am J Otolaryngol 27:161–165PubMed
Zurück zum Zitat Gold SL, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J (2014) Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 13:1380–1386 Gold SL, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J (2014) Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 13:1380–1386
Zurück zum Zitat Sticherling M, Mrowietz U, Augustin M, Thaçi D, Melzer N, Hentschke C, Kneidl J, Sieder C, Reich K (2017) Secukinumab is superior to fumaric acid esters in treating subjects with moderate to severe plaque psoriasis who are Naïve to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol Br J Dermatol 177:1024–1032PubMed Sticherling M, Mrowietz U, Augustin M, Thaçi D, Melzer N, Hentschke C, Kneidl J, Sieder C, Reich K (2017) Secukinumab is superior to fumaric acid esters in treating subjects with moderate to severe plaque psoriasis who are Naïve to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol Br J Dermatol 177:1024–1032PubMed
Zurück zum Zitat Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C (2008) Topical polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 158:1329–1338PubMed Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C (2008) Topical polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 158:1329–1338PubMed
Zurück zum Zitat Stockfleth E, Kerl H, Zwingers T, Willers C (2011) Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101–1108PubMed Stockfleth E, Kerl H, Zwingers T, Willers C (2011) Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101–1108PubMed
Zurück zum Zitat Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG (2017) Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol 76:655–661PubMed Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG (2017) Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol 76:655–661PubMed
Zurück zum Zitat Subissi A, Monti D, Togni G, Mailland F (2010) Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70:2133–2152PubMed Subissi A, Monti D, Togni G, Mailland F (2010) Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70:2133–2152PubMed
Zurück zum Zitat Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, Jacovella J (2015) Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 172:1103–1110PubMed Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, Jacovella J (2015) Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 172:1103–1110PubMed
Zurück zum Zitat Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR (2008) Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 111:1371–1379PubMed Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR (2008) Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 111:1371–1379PubMed
Zurück zum Zitat Thaçi D, Schöfer H (2005) Topische Antibiotika zur Therapie von Hautinfektionen. Hautarzt 56:381–396PubMed Thaçi D, Schöfer H (2005) Topische Antibiotika zur Therapie von Hautinfektionen. Hautarzt 56:381–396PubMed
Zurück zum Zitat Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M (2015) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73:400–409PubMed Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M (2015) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73:400–409PubMed
Zurück zum Zitat Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K (2019) Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. https://doi.org/10.1111/bjd.18696 CrossRefPubMedPubMedCentral Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K (2019) Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. https://​doi.​org/​10.​1111/​bjd.​18696 CrossRefPubMedPubMedCentral
Zurück zum Zitat Thiboutot D, Dréno B, Sanders V, Rueda MJ, Gollnick H (2020) Changes in the management of acne: 2009–2019. J Am Acad Dermatol 82:1268–1269PubMed Thiboutot D, Dréno B, Sanders V, Rueda MJ, Gollnick H (2020) Changes in the management of acne: 2009–2019. J Am Acad Dermatol 82:1268–1269PubMed
Zurück zum Zitat Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, Bettoli V, Casintahan F, Chow S, da Costa A, El Ouazzani T, Goh CL, Gollnick HPM, Gomez M, Hayashi N, Herane MI, Honeyman J, Kang S, Kemeny L, Kubba R, Lambert J, Layton AM, Leyden JJ, López-Estebaranz JL, Noppakun N, Ochsendorf F, Oprica C, Orozco B, Perez M, Piquero-Martin J, See JA, Suh DH, Tan J, Lozada VT, Troielli P, Xiang LF (2018) Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 78(2 Suppl 1):S1–S23.e1PubMed Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, Bettoli V, Casintahan F, Chow S, da Costa A, El Ouazzani T, Goh CL, Gollnick HPM, Gomez M, Hayashi N, Herane MI, Honeyman J, Kang S, Kemeny L, Kubba R, Lambert J, Layton AM, Leyden JJ, López-Estebaranz JL, Noppakun N, Ochsendorf F, Oprica C, Orozco B, Perez M, Piquero-Martin J, See JA, Suh DH, Tan J, Lozada VT, Troielli P, Xiang LF (2018) Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 78(2 Suppl 1):S1–S23.e1PubMed
Zurück zum Zitat Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S, Adapalene-BPO Study Group (2007) Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 57:791–799PubMed Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S, Adapalene-BPO Study Group (2007) Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 57:791–799PubMed
Zurück zum Zitat Thurgar E, Barton S, Karner C, Edwards SJ (2016) Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. Health Technol Assess 20(v–vi):1–486PubMedCentral Thurgar E, Barton S, Karner C, Edwards SJ (2016) Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. Health Technol Assess 20(v–vi):1–486PubMedCentral
Zurück zum Zitat Udompataikul M, Limpa-o-vart D (2012) Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol 11:366–374PubMed Udompataikul M, Limpa-o-vart D (2012) Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol 11:366–374PubMed
Zurück zum Zitat Valente Duarte de Sousa IC (2014) Novel pharmacological approaches for the treatment of acne vulgaris. Expert Opin Investig Drugs 23:1389–1410PubMed Valente Duarte de Sousa IC (2014) Novel pharmacological approaches for the treatment of acne vulgaris. Expert Opin Investig Drugs 23:1389–1410PubMed
Zurück zum Zitat Wananukul S, Limpongsanuruk W, Singalavanija S, Wisuthsarewong W (2006) Comparison of dexpanthenol and zinc oxide ointment with ointment base in the treatment of irritant diaper dermatitis from diarrhea: a multicenter study. J Med Assoc Thai 89:1654–1658PubMed Wananukul S, Limpongsanuruk W, Singalavanija S, Wisuthsarewong W (2006) Comparison of dexpanthenol and zinc oxide ointment with ointment base in the treatment of irritant diaper dermatitis from diarrhea: a multicenter study. J Med Assoc Thai 89:1654–1658PubMed
Zurück zum Zitat Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H (2021) Update „Systemic treatment of atopic dermatitis“ of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges: 19:151–168PubMed Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Diepgen T, Fölster-Holst R, Kahle J, Kapp A, Nemat K, Peters E, Schlaeger M, Schmid-Grendelmeier P, Schmitt J, Schwennesen T, Staab D, Traidl-Hoffmann C, Werner R, Wollenberg A, Worm M, Ott H (2021) Update „Systemic treatment of atopic dermatitis“ of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges: 19:151–168PubMed
Zurück zum Zitat Werner RN, Westfechtel L, Dressler C, Nast A (2017) Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect 93:155–161PubMed Werner RN, Westfechtel L, Dressler C, Nast A (2017) Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect 93:155–161PubMed
Zurück zum Zitat Wheat CM, Bickley RJ, Hsueh YH, Cohen BA (2017) Current trends in the use of two combination antifungal/corticosteroid creams. J Pediatr 186:192–195PubMed Wheat CM, Bickley RJ, Hsueh YH, Cohen BA (2017) Current trends in the use of two combination antifungal/corticosteroid creams. J Pediatr 186:192–195PubMed
Zurück zum Zitat Williamson DA, Carter GP, Howden BP (2017) Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev 30(3):827–860PubMedPubMedCentral Williamson DA, Carter GP, Howden BP (2017) Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev 30(3):827–860PubMedPubMedCentral
Zurück zum Zitat Willy C, Stichling M, Müller M, Gatzer R, Kramer A, Vogt D (2016) Akute Maßnahmen beim „limb salvage“ – Prozedere Teil 2. Debridement, Lavagetechniken und antiinfektiöse Strategien. Unfallchirurg 119:388–399PubMed Willy C, Stichling M, Müller M, Gatzer R, Kramer A, Vogt D (2016) Akute Maßnahmen beim „limb salvage“ – Prozedere Teil 2. Debridement, Lavagetechniken und antiinfektiöse Strategien. Unfallchirurg 119:388–399PubMed
Zurück zum Zitat Wohlrab J (2016) Topika und deren Einsatz in der Dermatologie. J Dtsch Dermatol Ges 14:1061–1071PubMed Wohlrab J (2016) Topika und deren Einsatz in der Dermatologie. J Dtsch Dermatol Ges 14:1061–1071PubMed
Zurück zum Zitat Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B, Fölster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen DJ, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder JF, Ring J (2020) Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 34:2717–2744PubMed Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B, Fölster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen DJ, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder JF, Ring J (2020) Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 34:2717–2744PubMed
Zurück zum Zitat Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 21:2933–2948PubMed Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 21:2933–2948PubMed
Zurück zum Zitat Worret WI, Fluhr JW (2006) Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges 4:293–300PubMed Worret WI, Fluhr JW (2006) Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges 4:293–300PubMed
Zurück zum Zitat Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Gold SLF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74:945–973.e33PubMed Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Gold SLF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74:945–973.e33PubMed
Zurück zum Zitat Zhu TH, Nakamura M, Abrouk M, Farahnik B, Koo J, Bhutani T (2016) Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: a review. J Dermatolog Treat 2:1–8 Zhu TH, Nakamura M, Abrouk M, Farahnik B, Koo J, Bhutani T (2016) Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: a review. J Dermatolog Treat 2:1–8
Zurück zum Zitat van Zuuren EJ, Fedorowicz Z, Arents BWM (2017) Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 177:1256–1271PubMed van Zuuren EJ, Fedorowicz Z, Arents BWM (2017) Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol 177:1256–1271PubMed
Zurück zum Zitat van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MMD, Arents BWM, Carter B, Charland L (2019) Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 181:65–79PubMedPubMedCentral van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MMD, Arents BWM, Carter B, Charland L (2019) Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol 181:65–79PubMedPubMedCentral
Zurück zum Zitat van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J (2021) Rosacea: new concepts in classification and treatment. Am J Clin Dermatol 22:457–465PubMedPubMedCentral van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J (2021) Rosacea: new concepts in classification and treatment. Am J Clin Dermatol 22:457–465PubMedPubMedCentral
Metadaten
Titel
Hauterkrankungen
verfasst von
Prof. Dr. med. Hans Merk
Dr. rer. nat. Judith Günther
Copyright-Jahr
2022
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-66303-5_35

Passend zum Thema

ANZEIGE

Umfrage: Topika mit Dexpanthenol bei Radiodermatitis empfohlen

In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1]. 

ANZEIGE

Handekzem: Adhärenz bei topischer Therapie nicht zufriedenstellend

Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1]. 

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bayer Vital GmbH

Passend zum Thema

ANZEIGE

Die entscheidende Rolle des Mikrobioms bei atopischer Dermatitis

Bei atopischer Dermatitis besteht eine direkte Korrelation des Schweregrad der Erkrankung und einer verminderten Diversität des Mikrobioms. Studiendaten zeigen, dass durch eine Behandlung mit Emollienzien plus, die Besiedelung mit Staphylokokken reduziert und das Mikrobiom stabilisiert werden kann.

ANZEIGE

Welche Bedeutung hat das Mikrobiom bei Wundheilung und AD?

Warum hat das Mikrobiom der Haut in den letzten Jahren in der Wissenschaft an enormer Bedeutung gewonnen? Welche Möglichkeiten ergeben sich dadurch für die Behandlung bei Hautkrankheiten wie atopischer Dermatitis und der Wundheilung? Dies erläutert Prof. Thomas Luger im Interview.

ANZEIGE

Neueste Erkenntnisse zum Hautmikrobiom: vier Experten im Gespräch

Content Hub

Die Experten Prof. Luger (Münster), Prof. Zuberbier (Berlin), Prof. Thaçi (Lübeck) und PD Dr. Jansen (Essen) erörtern im von La Roche Posay unterstützen Expertenworkshop die Bedeutung des Mikrobioms für verschiedene Hautkrankheiten wie atopische Dermatitis, Akne oder Rosazea.

La Roche Posay